How can artificial intelligence, research funding, and collaboration accelerate the fight against breast cancer?

In this NYSE Live interview, Wendy Holmes, Advisory Board Member at the Breast Cancer Research Foundation (BCRF) and Private Wealth Advisor at UBS, discusses BCRF's new $100 million venture fund, breakthroughs in breast cancer research, and how emerging technologies are helping improve early detection and patient outcomes.

Holmes explains that the venture fund was created to address a critical challenge facing many promising medical innovations: bridging the gap between scientific discovery and commercial implementation. By providing funding and support to researchers and entrepreneurs, BCRF aims to help life-changing innovations move from the laboratory into real-world healthcare applications.

A major focus of the conversation is the role of artificial intelligence in advancing breast cancer screening and risk assessment. Holmes highlights Clarity Breast, a company founded by Harvard researcher Dr. Connie Lehman, which developed an AI-powered mammography tool capable of assessing breast cancer risk years before a potential diagnosis. She explains that the technology represents a significant advancement in predictive screening and personalized risk evaluation.

The interview also explores the importance of collaboration within the scientific community. Drawing on insights from a recent gathering of cancer researchers, Holmes discusses how BCRF fosters a collaborative environment that encourages information sharing and partnership among researchers working toward the common goal of improving outcomes for patients worldwide.

Another key theme is the scale of BCRF's research efforts. Holmes notes that the organization is supporting hundreds of researchers globally and investing tens of millions of dollars annually to fund innovative projects focused on prevention, detection, treatment, and survivorship.

The conversation further examines the concerning trend of increasing breast cancer incidence among younger women. Holmes emphasizes the importance of awareness, routine screening, and early detection while encouraging individuals to better understand their personal risk factors and family health histories.

The discussion also addresses the evolving understanding of breast cancer risk. Holmes notes that many breast cancer cases occur without a known genetic link, highlighting the need for continued research and advanced technologies that can identify risk factors beyond traditional genetic screening methods.

Additionally, Holmes reflects on her personal connection to BCRF and its mission. Inspired by founder Evelyn Lauder and informed by years working with philanthropic individuals and families, she discusses the importance of strategic giving, research funding, and long-term investment in scientific breakthroughs.

Throughout the interview, Holmes shares insights on breast cancer research, artificial intelligence, healthcare innovation, philanthropy, early detection, women's health, medical technology, and the future of cancer care.

Disclaimer: Informational content only. NYSE does not endorse or recommend investments, strategies, companies, products, or services discussed.

#NYSE #NYSELive #BCRF #WendyHolmes #BreastCancerAwarenessMonth #BreastCancerResearch #ArtificialIntelligence #AI #HealthcareInnovation #WomensHealth #CancerResearch #Philanthropy